EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation
Open Access
- 29 November 2018
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 132 (22) , 2351-2361
Abstract
There is a Blood Commentary on this article in this issue.Keywords
This publication has 34 references indexed in Scilit:
- Hodgkin lymphomaJournal of Clinical Investigation, 2012
- Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantationBlood, 2012
- Histology and Time to Progression Predict Survival for Lymphoma Recurring after Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2011
- Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein–Barr virus-associated lymphomaCytotherapy, 2011
- A novel latent membrane 2 transcript expressed in Epstein-Barr virus–positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapyBlood, 2010
- Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipientsBlood, 2010
- Hematopoietic Stem Cell Transplantation for Refractory or Recurrent Non-Hodgkin Lymphoma in Children and AdolescentsTransplantation and Cellular Therapy, 2010
- HIV infection and lymphomaJournal of Clinical Pathology, 2007
- Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transferBlood, 2007
- Treatment of solid organ transplant recipients with autologous Epstein Barr virus–specific cytotoxic T lymphocytes (CTLs)Blood, 2006